Lifesci Capital Has Optimistic Outlook of CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities research analysts at Lifesci Capital raised their Q1 2025 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research note issued to investors on Tuesday, March 11th. Lifesci Capital analyst M. Belghiti now anticipates that the biopharmaceutical company will post earnings of ($2.74) per share for the quarter, up from their prior forecast of ($2.95). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. Lifesci Capital also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($3.00) EPS, Q3 2025 earnings at ($3.28) EPS, Q4 2025 earnings at ($3.59) EPS and FY2025 earnings at ($12.62) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.24.

CRBP has been the subject of a number of other research reports. StockNews.com upgraded Corbus Pharmaceuticals to a “sell” rating in a research report on Thursday, March 6th. Jefferies Financial Group decreased their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research report on Wednesday. William Blair began coverage on Corbus Pharmaceuticals in a research report on Friday, February 28th. They issued an “outperform” rating for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.13.

Corbus Pharmaceuticals Stock Up 5.8 %

NASDAQ:CRBP opened at $6.79 on Friday. Corbus Pharmaceuticals has a 52-week low of $6.38 and a 52-week high of $61.90. The firm has a market cap of $82.70 million, a P/E ratio of -1.45 and a beta of 2.63. The business’s 50-day moving average price is $9.44 and its 200 day moving average price is $18.99.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Vestcor Inc acquired a new stake in Corbus Pharmaceuticals during the 3rd quarter worth about $64,000. Wells Fargo & Company MN lifted its holdings in shares of Corbus Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 2,195 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $84,000. Deutsche Bank AG lifted its holdings in shares of Corbus Pharmaceuticals by 46.8% during the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 2,616 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $101,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.